MacroGenics axes ADC drug following Phase II failure in prostate cancer

By Yahoo! Finance   |   1 month ago
MacroGenics axes ADC drug following Phase II failure in prostate cancer

MacroGenics is discontinuing the development of vobramitamab duocarmazine (vobra duo) after disappointing results in a Phase II study for prostate cancer.

Read More

Did you find this insightful?